Compare AEHL & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | ENVB |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 8.1M |
| IPO Year | 2009 | 2000 |
| Metric | AEHL | ENVB |
|---|---|---|
| Price | $8.05 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 105.3K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.56 |
| 52 Week High | $8.92 | $13.25 |
| Indicator | AEHL | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 46.85 |
| Support Level | $0.64 | $1.17 |
| Resistance Level | $8.92 | $1.53 |
| Average True Range (ATR) | 1.10 | 0.11 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 79.07 | 53.49 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.